Sangamo Therapeutics Inc. (SGMO)
NASDAQ: SGMO
· Real-Time Price · USD
0.48
-0.02 (-4.57%)
At close: Jun 13, 2025, 3:59 PM
-4.57% (1D)
| Bid | 0.43 |
| Market Cap | 118.21M |
| Revenue (ttm) | 63.76M |
| Net Income (ttm) | -79.45M |
| EPS (ttm) | -0.36 |
| PE Ratio (ttm) | -1.34 |
| Forward PE | -1.43 |
| Analyst | Buy |
| Ask | 0.52 |
| Volume | 3,407,676 |
| Avg. Volume (20D) | 7,031,209 |
| Open | 0.49 |
| Previous Close | 0.50 |
| Day's Range | 0.47 - 0.51 |
| 52-Week Range | 0.30 - 3.18 |
| Beta | 1.21 |
About SGMO
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol SGMO
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for SGMO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
-38.4%
Sangamo Therapeutics shares are trading lower afte...
Unlock content with
Pro Subscription
2 months ago
-4.73%
Sangamo Therapeutics shares are trading higher after the company announced it entered a capsid license agreement with Lilly.
1 month ago · seekingalpha.com
Sangamo Therapeutics, Inc. (SGMO) Q1 2025 Earnings Call TranscriptSangamo Therapeutics, Inc. (NASDAQ:SGMO ) Q1 2025 Earnings Conference Call May 12, 2025 6:30 PM ET Company Participants Louise Wilkie - Vice President, Investor Relations and Corporate Communications ...
2 months ago · seekingalpha.com
Sangamo Therapeutics: Scope Goes Beyond That Of Recent Eli Lilly Licensing DealSangamo Therapeutics, Inc.'s deal with Eli Lilly to develop genomic medicines for CNS using the STAC-BBB AAV capsid brings in an $18M upfront payment and the potential to earn $1.4B in milestone payme...
